{
    "pmcid": "11236199",
    "qa_pairs": {
        "How does the presence of linoleic acid in the fatty acid binding pocket (FABP) affect the SARS-CoV-2 spike protein?": [
            "It stabilizes the RBD in the 'down' conformation, preventing premature activation.",
            "It enhances the binding affinity of the spike protein to the ACE2 receptor.",
            "It increases the variability of the receptor binding domain (RBD).",
            "It reduces the overall glycosylation of the spike protein."
        ],
        "What is a key consideration for designing nanobodies to target the receptor binding domain (RBD) of SARS-CoV-2?": [
            "Accounting for local variations in the receptor binding motif (RBM) to ensure effective targeting.",
            "Focusing solely on the conserved S2 domain for broad reactivity.",
            "Avoiding regions with any structural conservation to prevent cross-reactivity.",
            "Targeting only the glycosylation sites to enhance binding specificity."
        ],
        "What structural feature of the SARSr-CoV spike proteins is conserved and suggests potential for cross-reactive nanobody design?": [
            "The high degree of structural conservation in the S2 and N-terminal domains.",
            "The unique glycosylation patterns that differ from SARS-CoV-2.",
            "The variable receptor binding motif (RBM) within the RBD.",
            "The absence of linoleic acid in the fatty acid binding pocket (FABP)."
        ],
        "What therapeutic potential do nanobodies have according to the structural insights from the study?": [
            "They could offer broad neutralization across SARS-CoV-2 variants and other SARSr-CoVs.",
            "They are limited to targeting only SARS-CoV-2 without cross-reactivity.",
            "They are designed to enhance the glycosylation of the spike protein.",
            "They are intended to destabilize the spike protein conformation."
        ],
        "Why is targeting the glycan shield important in the design of nanobodies against SARS-CoV-2?": [
            "To penetrate the glycan shield and access conserved epitopes obscured by glycans.",
            "To increase the size of nanobodies for better binding.",
            "To ensure nanobodies bind only to variable regions of the spike protein.",
            "To avoid any interaction with the fatty acid binding pocket (FABP)."
        ]
    }
}